Correctly identifying cytokine pathways that are dysregulated in any given rheumatology patient could lead to better use of current biologic therapies, said a presenter at the 2022 Association of Women in Rheumatology annual conference.
The dual interleukin-17 inhibitor was effective both in patients for whom TNF inhibitors failed and those who had never received a biologic disease-modifying antirheumatic drug in two trials.